Initial Results in Clinical Study Show Promise for Stem Cell Therapy for Treatment of ALS

BrainStorm Cell Therapeutics’ NurOwn technology, developed for the treatment of ALS, shows hints of promising results in its current Phase I (safety) clinical trial. These preliminary results, in a small number of patients, suggest that BrainStorm’s stem cell therapy could help slow the progression of ALS. The next steps will be to test different doses, as well as conduct a larger Phase II study to evaluate efficacy and safety.

Click here to read more.

Share this: